Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects

Journal of Medicinal Chemistry

Volumn 58, Issue 15, 2015, Pages 6048-6057

  Wada, Yasuhiro ^a,b   Shirahashi, Hiromitsu ^a   Iwanami, Taisuke ^a   Ogawa, Masami ^a   Nakano, Seiji ^a   Morimoto, Akifumi ^a   Kasahara, Ken Ichi ^a   Tanaka, Eiichi ^a   Takada, Yoshio ^a   Ohashi, Shigeki ^a   Mori, Mutsuhiro ^a   Shuto, Satoshi ^b  

^a ASAHI KASEI PHARMA CORPORATION   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; INDAZOLE DERIVATIVE; ISOPRENALINE; N [3 [1 HYDROXY 2 [2 [(3 ISOPROPYL 1H INDAZOL 6 YL)OXY]ETHYLAMINO]ETHYL]PHENYL]METHANESULFONAMIDE; N [3 [1 HYDROXY 2 [2 [(3 METHYL 1H INDAZOL 6 YL)OXY]ETHYLAMINO]ETHYL]PHENYL]METHYLSULFONAMIDE; NORADRENALIN; SILODOSIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOLOGICAL ACTIVITY; BLADDER; BLADDER MUSCLE; BLOOD PRESSURE; CALLITHRIX; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; EC50; FEMALE; HEART RATE; HUMAN; MALE; NONHUMAN; RAT; RESEARCH; SMOOTH MUSCLE RELAXATION; STRUCTURE ACTIVITY RELATION; ANIMAL; CARDIOVASCULAR SYSTEM; CHEMISTRY; DRUG EFFECTS;

ADRENERGIC BETA-3 RECEPTOR AGONISTS; ANIMALS; CARDIOVASCULAR SYSTEM; HUMANS; INDAZOLES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84939137980     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00638     Document Type: Article

References (36)

1. Abrams, P.; Cardozo, L.; Fall, M.; Griffiths, D.; Rosier, P.; Ulmsten, U.; van Kerrebroeck, P.; Victor, A.; Wein, A. Standardisation Sub-committee of the International Continence, S. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society Neurourol. Urodyn. 2002, 21, 167-178 10.1002/nau.10052
2. Wein, A. J.; Rovner, E. S. Definition and epidemiology of overactive bladder Urology 2002, 60, 7-12 10.1016/S0090-4295(02)01784-3
3. Irwin, D. E.; Milsom, I.; Hunskaar, S.; Reilly, K.; Kopp, Z.; Herschorn, S.; Coyne, K.; Kelleher, C.; Hampel, C.; Artibani, W.; Abrams, P. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study Eur. Urol. 2006, 50, 1306-1315 10.1016/j.eururo.2006.09.019
4. Abrams, P.; Andersson, K. E. Muscarinic receptor antagonists for overactive bladder BJU Int. 2007, 100, 987-1006 10.1111/j.1464-410X.2007.07205.x
5. Chapple, C. R.; Khullar, V.; Gabriel, Z.; Muston, D.; Bitoun, C. E.; Weinstein, D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis Eur. Urol. 2008, 54, 543-562 10.1016/j.eururo.2008.06.047
6. Wagg, A.; Compion, G.; Fahey, A.; Siddiqui, E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience BJU Int. 2012, 110, 1767-1774 10.1111/j.1464-410X.2012.11023.x
7. Staskin, D. R.; MacDiarmid, S. A. Using anticholinergics to treat overactive bladder: the issue of treatment tolerability Am. J. Med. 2006, 119, 9-15 10.1016/j.amjmed.2005.12.011
8. Chapple, C. R.; Cardozo, L.; Nitti, V. W.; Siddiqui, E.; Michel, M. C. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability Neurourol. Urodyn. 2014, 33, 17-30 10.1002/nau.22505
9. Bylund, D. B.; Eikenberg, D. C.; Hieble, J. P.; Langer, S. Z.; Lefkowitz, R. J.; Minneman, K. P.; Molinoff, P. B.; Ruffolo, R. R., Jr.; Trendelenburg, U. International Union of Pharmacology Nomenclature of Adrenoceptors Pharmacol. Rev. 1994, 46, 121-136
10. 3-adrenergic receptor Science 1989, 245, 1118-1121 10.1126/science.2570461
11. 3-adrenoceptor mRNA in human tissues Eur. J. Pharmacol., Mol. Pharmacol. Sect. 1995, 289, 223-228 10.1016/0922-4106(95)90098-5
12. 3-adrenoceptor in human and rat detrusor muscle J. Urol. 1999, 161, 680-685 10.1016/S0022-5347(01)61994-3
13. 3-Adrenoceptors in human detrusor muscle Urology 2002, 59, 25-29 10.1016/S0090-4295(01)01635-1
14. 3-adrenoceptors in man J. Pharmacol. Exp. Ther. 2009, 328, 213-222 10.1124/jpet.108.142562
15. 3-adrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat J. Urol. 2001, 166, 1142-1147 10.1016/S0022-5347(05)65936-8
16. 3 adrenergic receptor agonists for the treatment of overactive bladder J. Med. Chem. 2014, 57, 1437-1453 10.1021/jm4017224
17. 3-adrenergic receptor agonists and evaluation of physical properties as potential overactive bladder therapies: part 5 J. Med. Chem. 2009, 52, 3063-3072 10.1021/jm9000709
18. 3-adrenergic receptor agonists: Part IV Bioorg. Med. Chem. Lett. 2008, 18, 5037-5040 10.1016/j.bmcl.2008.08.009
19. 3-adrenergic receptor agonists with good oral bioavailability. Part I J. Med. Chem. 2008, 51, 1925-1944 10.1021/jm701324c
20. 3 adrenergic receptor agonists with good oral bioavailability. 3. Phenylethanolaminotetraline (PEAT) skeleton containing biphenyl or biphenyl ether moiety J. Med. Chem. 2008, 51, 4804-4822 10.1021/jm800222k
21. 3 adrenergic receptor agonists with good oral bioavailability. Part II J. Med. Chem. 2008, 51, 4002-4020 10.1021/jm8000345
22. 3 adrenergic receptor agonists J. Med. Chem. 2006, 49, 2758-2771 10.1021/jm0509445
23. 3-adrenoceptor agonist, on bladder function J. Pharmacol. Exp. Ther. 2007, 321, 642-647 10.1124/jpet.106.115840
24. 3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog J. Pharmacol. Exp. Ther. 2007, 323, 202-209 10.1124/jpet.107.125757
25. 3-agonist ritobegron (KUC-7483) explored by in vitro and in vivo studies in the rat Naunyn-Schmiedeberg's Arch. Pharmacol. 2012, 385, 845-852 10.1007/s00210-012-0755-x
26. Malik, M.; van Gelderen, E. M.; Lee, J. H.; Kowalski, D. L.; Yen, M.; Goldwater, R.; Mujais, S. K.; Schaddelee, M. P.; de Koning, P.; Kaibara, A.; Moy, S. S.; Keirns, J. J. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study Clin. Pharmacol. Ther. 2012, 92, 696-706 10.1038/clpt.2012.181
27. Tyagi, P.; Tyagi, V.; Chancellor, M. Mirabegron: a safety review Expert Opin. Drug Saf. 2011, 10, 287-294 10.1517/14740338.2011.542146
28. Hayashi, R.; Kikuchi, T.; Arai, M.; Kurosawa, S.; Hasebe, K.; Kanie, S.; Ozono, S.; Otsuka, A. Benzylamine derivative or pharmaceutically acceptable acid addition salt thereof, and use thereof for medical purposes. WO2008093767, 2008.
29. 3-adrenergic receptor agonists Chem. Pharm. Bull. 2012, 60, 647-658 10.1248/cpb.60.647
30. 3-adrenergic receptor agonists Chem. Pharm. Bull. 2010, 58, 533-545 10.1248/cpb.58.533
31. 3-Adrenoceptor ligand development history through patent review Expert Opin. Ther. Pat. 2011, 21, 505-536 10.1517/13543776.2011.561316
32. 3-adrenergic receptor agonists Eur. J. Med. Chem. 2009, 44, 2533-2543 10.1016/j.ejmech.2009.01.022
33. 3-adrenergic receptor agonist, [3-[(2R)-[[(2R)-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]1H-indol-7-yloxy]acetic acid Chem. Pharm. Bull. 2005, 53, 184-198 10.1248/cpb.53.184
34. 1-Adrenoceptor subtypes Eur. J. Pharmacol. 1999, 375, 261-276 10.1016/S0014-2999(99)00222-8
35. 1-adrenoceptor agonists Curr. Top. Med. Chem. 2007, 7, 135-145 10.2174/156802607779318217
36. 1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia Clin. Ther. 2009, 31, 2489-2502 10.1016/j.clinthera.2009.11.024